Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and PD-1 Blockade Maintenance After CAR-T for B-cell Lymphoma
NCT07489989Phase 2Recruiting
- Sponsor
- Daihong Liu
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Daihong Liu. Started May 2025; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07489989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489989.